Novocure计划基于PANOVA-3，提交肿瘤电场治疗用于治疗不可切除、局部晚期胰腺癌的注册批准，并计划提交PANOVA-3的数据在即将举行的医学大会上进行公布。再鼎医药计划在中国提交注册申请。Zaiding Pharmaceutical (09688) rose more than 4%. As of press release, it rose 4.67% to HK$23.55, with a turnover of HK$16.0669 million.
The Zhitong Finance App learned that Zaiding Pharmaceutical (09688) rose by more than 4%. As of press release, it had risen 4.67% to HK$23.55, with a turnover of HK$16.0669 million.
According to the news, Zaiding Pharmaceutical and Novocure announced that the Phase 3 PANOVA-3 study, which is critical for tumor electric field treatment, has reached its main end, showing a statistically significant improvement in median overall survival (MoS) compared with the control group. PANOVA-3 evaluated tumor electric field therapy combined with gemcitabine and albumin-conjugated paclitaxel for first-line treatment of unresectable, locally advanced pancreatic cancer.
Based on Panova-3, NovoCure plans to submit registration approval for tumor electric field therapy to treat unresectable, locally advanced pancreatic cancer, and plans to submit PANOVA-3 data for publication at upcoming medical conferences. Zaiding Pharmaceutical plans to apply for registration in China.
